Endocrine Abstracts

BackgroundPembolizumab is a highly specific, monoclonal antibody directed against the programmed cell death receptor, PD-1 and its ligand PD-L1. It is licenced as an immunotherapy for use in locally advanced or metastatic urothelial cell carcinoma, amongst other malignancies. Whilst rare, endocrinopathies, including thyroid dysfunction, are recognised side effects of immunotherapy such as Pembroluzimab. However, hyperthyroidism is much less common than h...